COVID-19 computing consortium focusing on near-term COVID-19 therapies

By The Science Advisory Board staff writers

The COVID-19 High Performance Computing (HPC) Consortium said that it has entered a new phase of operation focused on helping researchers identify potential near-term therapies for COVID-19 patients.

With a greater volume of COVID-19 data now available, the public-private consortium said it has decided to focus on research projects that hold potential to help improve patient outcomes within a six-month timeframe.

The 43-member consortium was created in May by IBM, the White House Office of Science and Technology Policy, and the U.S. Department of Energy to bring together computing resources, software, and services to help researchers around the world understand COVID-19, its treatments, and potential cures.

In its new operational phase, the consortium said it's particularly interested in projects focused on:

  • Understanding and modeling patient response to the virus using large clinical datasets
  • Learning and validating vaccine response models from multiple clinical trials
  • Evaluating combination therapies using repurposed molecules
  • Epidemiological models driven by large multimodal datasets

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?